Compare ORGO & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORGO | GAIN |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.0M | 556.7M |
| IPO Year | 2016 | N/A |
| Metric | ORGO | GAIN |
|---|---|---|
| Price | $3.94 | $13.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.00 | ★ $14.75 |
| AVG Volume (30 Days) | ★ 473.3K | 175.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $482,043,000.00 | N/A |
| Revenue This Year | $8.14 | $5.67 |
| Revenue Next Year | $6.33 | $6.44 |
| P/E Ratio | ★ N/A | $4.38 |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $2.61 | $11.42 |
| 52 Week High | $7.08 | $15.25 |
| Indicator | ORGO | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 46.03 |
| Support Level | $3.89 | $13.60 |
| Resistance Level | $4.10 | $14.11 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 64.04 | 24.62 |
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.